Skip to main content
. 2017 Aug 29;8:445. doi: 10.3389/fneur.2017.00445

Table 1.

Demographic and clinical characteristics of the Parkinson’s disease (PD) and spinocerebellar ataxia type 3 (SCA3) patients.

PD group (No.) Age (years) Sex Disease duration (years) Motor/total UPDRS (more affected side) Hoehn and Yahr stage Medication (daily dose in mg) (LED)
1 66 F 3 38/55 (L) 2.5 Levodopa 300 (300)
2 70 M 8 48/64 (L) 3 Levodopa 350, trihexyphenidyl 3, amantadine 300, rotigotine 4 (770)
3 67 F 7 18/22 (L) 2 Levodopa 300, biperiden 4, ropinirole PR 4 (380)
4 57 M 6 27/33 (L) 2 Levodopa 300, pramipexole 0.75, amantadine 300 (675)
5 79 F 5 32/45 (L) 2.5 Levodopa 100, amantadine 100, propranolol 20 (200)
6 82 M 5 27/41 (R) 2.5 Levodopa 300, entacapone 600, amantadine 100, propranolol 30 (499)
7 75 M 1 16/31 (R) 2 Levodopa 100 (100)
8 80 M 3 24/30 (L) 2 Levodopa 200 (200)
9 62 M 2 28/40 (R) 2 Levodopa 300, biperiden 3, ropinirole 0.75 (315)
10 53 M 3 15/26 (R) 2 Levodopa 200 (200)

SCA3 group (No.) Age (years) Sex Disease duration (years) Clinical rating scale for cerebellar functiona Abnormal CAG repeat number Medication (daily dose in mg) (LED)

1 47 M 20 13 73 Levodopa 100, amantadine 100, baclofen 20, piracetam 2,400 (200)
2 62 F 3 11 62 Amantadine 150, biperiden 3 (150)
3 43 M 16 21 82 Amantadine 300, trihexyphenidyl 4, tizanidine 9, flunarizine HCl 15 (300)
4 75 F 13 24 66 Alprazolam 0.25 (0)
5 30 F 4 12 76 Tizanidine 3, amantadine 300 (300)
6 59 F 10 22 71 None (0)
7 62 M 2 12 66 Piracetam 2,400 (0)
8 30 F 3 12 76 Amantadine 150 (150)
9 39 F 3 14 74 Levodopa 100, amantadine 100 (200)

aThe rating scale was developed by S. Massaquoi and M. Hallett. A higher score represents a more severe cerebellar dysfunction. The maximal score of the scale is 30 [for a detail, see Wessel et al. (19)].

F, female; L, left; LED, l-DOPA equivalent dose (20); M, male; R, right; UPDRS, unified PD rating scale.